NFA
CPRX icon

Nationwide Fund Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Nationwide Fund Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-40,137
Closed -$101K – 464
2017
Q3 		$101K Hold
40,137
– – ﹤0.01% 2894
2017
Q2 		$111K Buy
+40,137
New +$83.8K ﹤0.01% 2853
2016
Q2 		– Sell
-48,423
Closed -$57K – 3270
2016
Q1 		$57K Hold
48,423
– – ﹤0.01% 2962
2015
Q4 		$119K Hold
48,423
– – ﹤0.01% 2779
2015
Q3 		$145K Hold
48,423
– – ﹤0.01% 2729
2015
Q2 		$200K Buy
+48,423
New +$193K ﹤0.01% 2711

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Nationwide Fund Advisors's CPRX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q4 2017, closing a stake of 40,137 shares — an estimated $101K sold.

Nationwide Fund Advisors first reported a position in CPRX in Q2 2015 and held it in 6 quarters. The position peaked at $200K in Q2 2015. 105 funds tracked by Wall St. Rank hold CPRX as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Catalyst Pharmaceutical position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 40,137 Catalyst Pharmaceutical shares in Q4 2017, an estimated $101K.
  • Nationwide Fund Advisors first reported a position in Catalyst Pharmaceutical in Q2 2015 and held it in 6 quarters.
  • Nationwide Fund Advisors's Catalyst Pharmaceutical position peaked at $200K in Q2 2015.
  • 105 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.